Home / Video / Clinical Trials and Drug Approval

Clinical Trials and Drug Approval

Ionis Pharmaceuticals - Industry Updates On Drug Development (2018 MDF Annual Conference)

Laurence Mignon, PhD, IONIS Pharmaceuticals provides an update on their drug development efforts in the DM field, 

AMO Pharma Ltd. - Industry Updates On Drug Development (2018 MDF Annual Conference)

Joseph P. Horrigan, MD, from AMO Pharma Ltd. provides an update on their drug development efforts in the DM field. 

Expansion Therapeutics - Industry Updates On Drug Development (2018 MDF Annual Conference)

Representatives from biotech and pharma companies will provide updates on their drug development efforts in the DM field. Matthew Disney, PhD, Expansion Therapeutics

Locana - Industry Updates On Drug Development (2018 MDF Annual Conference)

Ranjan Batra, PhD, Locana, provides an update on their drug development efforts in the DM field. 

Accelerating The Search For Therapies: What's Happening, What's Next (2018 MDF Annual Conference)

Dr. Elizabeth Ackermann reports on the results of the 3-year MDF and Wyck Foundation-funded drug development acceleration effort, MDF 3.0, and introduces MDF’s new initiative, MDF 4.0, including the $1M gene editing project, the Myotonic Dystrophy Clinical Research Network study and other aggressive therapy development programs.

Bringing the Patient Voice to CNS Targeting Drug Development 2: Industry Observations and Feedback

Video #2 from the session: Bringing the Patient Voice to CNS Targeting Drug Development in DM. Dr. Gersham Dent, a neuroscientist working on the DM1 drug development program at Biogen, provides observations on panelists' CNS symptom experiences with regard to possible endpoint identification for future clinical trials of CNS-targeting therapies. From the 2017 MDF Annual Conference.

Bringing the Patient Voice to CNS Targeting Drug Development in DM

MDF community members reported on the impact of myotonic dystrophy on the brain from their individual perspectives as people living with DM1, DM2 and as caregivers. Additional insights and comments were provided by members of the conference audience. The session input will be published and used to help drug developers understand the impact of DM on the brain from the patient perspective, and begin to identify clinical trial endpoints. From the 2017 MDF Annual Conference.

Patient-Focused Drug Development Meeting, Part 2 (2016 MDF Annual Conference)

Watch Patient-Focused Drug Development Meeting, Part 2, a video from the 2016 MDF Annual Conference.

Patient-Focused Drug Development Meeting, Part 1 (2016 MDF Annual Conference)

Watch Patient-Focused Drug Development Meeting, Part 1, a video from the 2016 MDF Annual Conference.

Clinical Trials Training

The Myotonic Dystrophy Foundation presents a training video for clinical trials participants, presented by Dr. Bruce Wentworth of Genzyme, and Jeanne Dekdebrun and Elizabeth Luebbe of the University of Rochester.

Partners

© Myotonic Dystrophy Foundation. All rights reserved.